What is the equivalent dose of IV Furosemide (Lasix) for a patient taking Bumetanide (Bumex) 1 mg twice daily (bid)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Equivalent IV Furosemide Dose for Patient on Bumetanide 1 mg BID

The equivalent IV furosemide dose for a patient taking bumetanide 1 mg twice daily is 80-100 mg IV furosemide.

Conversion Ratios and Equivalence

Loop diuretics are commonly used in the management of fluid overload, particularly in heart failure patients. When converting between bumetanide and furosemide, the following equivalence ratios should be considered:

  • Bumetanide is approximately 40-50 times more potent than furosemide on a milligram-to-milligram basis 1, 2

  • For oral medications:

    • 1 mg oral bumetanide ≈ 40 mg oral furosemide
    • Therefore, 1 mg BID oral bumetanide ≈ 40 mg BID (80 mg total) oral furosemide
  • For IV conversion:

    • IV formulations of both medications are approximately 2-3 times more potent than their oral counterparts 2
    • Therefore, 80 mg oral furosemide equivalent would convert to approximately 40 mg IV furosemide per dose

Dosing Algorithm

  1. Calculate oral furosemide equivalent:

    • 1 mg bumetanide BID = 2 mg total daily bumetanide
    • 2 mg bumetanide × 40 = 80 mg total daily furosemide
  2. Account for IV bioavailability:

    • Since IV furosemide is approximately twice as potent as oral furosemide, the equivalent IV dose would be 40-50 mg per dose
  3. Consider frequency:

    • If giving as a single IV dose, use 80-100 mg IV furosemide
    • If maintaining BID dosing, use 40-50 mg IV furosemide per dose

Clinical Considerations

The European Society of Cardiology guidelines recommend that when converting from oral to IV diuretics, the initial IV dose should be at least equal to the pre-existing oral dose 3. For patients already on chronic diuretic therapy, the IV bolus should be equivalent to or higher than the oral dose they were taking.

According to the FDA label for furosemide, IV therapy should be used only in patients unable to take oral medication or in emergency situations, with an initial dose of 20-40 mg given as a single dose, injected slowly over 1-2 minutes 4. However, this is for diuretic-naïve patients. For patients already on chronic diuretic therapy, higher doses are typically required.

Important Caveats and Monitoring

  • Monitor closely for excessive diuresis: Rapid fluid shifts can lead to electrolyte abnormalities and hypotension
  • Watch for electrolyte disturbances: Both medications can cause hypokalemia, hyponatremia, and hypochloremia
  • Renal function: Monitor creatinine and BUN as excessive diuresis can worsen renal function
  • Individual response: Some patients may require dose adjustments based on clinical response
  • Duration of action: IV furosemide has a shorter duration of action (6-8 hours) compared to oral bumetanide (4-6 hours) 3

Special Situations

For patients with severe heart failure or renal impairment, higher doses may be required due to decreased drug delivery to the site of action. In these cases, continuous infusion of furosemide (at a rate not greater than 4 mg/min) may be more effective than bolus dosing 4.

For patients with acute pulmonary edema, the FDA label recommends an initial dose of 40 mg IV furosemide, which may be increased to 80 mg if a satisfactory response does not occur within 1 hour 4.

By following these guidelines and monitoring the patient's response carefully, you can effectively transition a patient from oral bumetanide to IV furosemide while maintaining appropriate diuretic effect.

References

Research

Bumetanide: a new loop diuretic (Bumex, Roche Laboratories).

Drug intelligence & clinical pharmacy, 1983

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.